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Nuggehally R SrinivasDear editor-in-chief
The recently published article in the esteemed journal
entitled “Design and evaluation of Lumefantrine – Oleic
acid self nanoemulsifying ionic complex for enhanced
dissolution” [1], describes an in-depth research pertaining
to the formulation attributes of lumefantrine, an important
ani-malarial drug, to enhance its in vitro dissolution
and thereby improving its bioavailability upon oral
administration. As discussed by authors’ poor solubility of
novel chemical entities (NCEs) leads to lack of in vivo
translation of the promising in vitro attributes of NCEs
because they fail to achieve adequate exposure needed to
modulate the target or receptors under in vivo conditions
[1]. Since lumefantrine has a low and variable bioavailability
dependent on the food intake, it is extremely challenging to
maintain the threshold levels of the drug needed to combat
malarial infections [2]. While the dosing recommendation
of lumefantrine takes into consideration food intake
especially milk consumption to improve its solubility
and bioavailability, it may be difficult to maintain the
same food intake conditions within the same individual
or across individuals who are suffering from malaria.
Therefore, the need of a formulation strategy to overcome
this barrier and maximize the delivery of lumefantrine
was warranted. In this context, the development and
complete characterization of a self nanoemulsifying delivery
system is the step in the right direction as it potentially
eliminates the influence of food on the bioavailability of
lumefantrine [1].
In this interesting work, a complete optimization of the
nanoemulsifying delivery system has been achieved –
consideration has been given to the various excipients
and the composition needed to maximize the dissolution
of lumefantrine [1]. Interestingly, comparative dissolution
profiles of the current marketed formulation vs the newly
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reproduction in any medium, provided the orunequivocally confirmed the advantages of the new
lumefantrine formulation [1]. While the dependency on
fat contents is totally removed, the pH dependency has
also been optimized such that the new lumefantrine
formulation would be solubilized across the expected pH
ranges of 1.2 to 6.8 in the human gastrointestinal tract [1].
However, there is one important missing link in the
current research that would have further enhanced the
utility of the work. The lack of in vivo pharmacokinetic
study brings in a void although one may justify that
in vitro performance of the new lumefantrine formulation
is a good surrogate of its in vivo pharmacokinetics and
exposure in humans. It is acknowledged that it may be
difficult to perform a human clinical study because of
plethora of reasons, however, one should at least consider
performing a non-clinical study (say in dogs), which is
geared towards establishing the in vivo pharmacokinetics
of the new lumefantrine formulation in comparison with
the marketed formulation. Since the ultimate goal of
developing a new lumefantrine formulation is to enable a
consistent and controlled delivery of lumefantrine in
patients with malaria, such in vivo pharmacokinetic data
would have supported the true utility of the new formulation
vs the current marketed formulation. Another important
reason to do an in vivo pharmacokinetic study stems from
the fact that this class of compounds are prone to be
absorbed through lymphatic transport. In this context,
lymphatic transport of halofantrine, another anti-malarial
drug, has been well established [3,4]. Hence, one key
question that would remain unanswered would be: does
the new lumefantrine self nanoemulsifying formulation
be viable for lymphatic transport mechanism? and/or due
to change in its composition and avoidance of food intake,
would it circumvent lymphatic transport mechanism?
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